journal
MENU ▼
Read by QxMD icon Read
search

Current Oncology Reports

journal
https://www.readbyqxmd.com/read/29423750/the-requirement-for-increasingly-effective-societal-cancer-control-efforts
#1
REVIEW
Maurie Markman
No abstract text is available yet for this article.
February 9, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29411148/from-a-patient-advocate-s-perspective-does-cancer-immunotherapy-represent-a-paradigm-shift
#2
REVIEW
Debra L Madden
PURPOSE OF REVIEW: In 2016, the American Society of Clinical Oncology (ASCO) announced immunotherapy as the year's top cancer advance in its "Clinical Cancer Advances 2016: ASCO's Annual Report on Progress Against Cancer." Further, ASCO again named "Immunotherapy 2.0" as the 2017 advance of the year, emphasizing the recent, rapid pace of research into new agents that harness and enhance the innate abilities of the immune system to recognize and fight cancers-and stressing that such agents have extended the lives of many patients with late-stage cancers for which there have been few treatment options...
February 7, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29411144/olfactory-neuroblastoma
#3
REVIEW
Ahmed S Abdelmeguid
PURPOSE OF REVIEW: To provide a comprehensive review of the literature focusing on the recent advances in the diagnosis and management of olfactory neuroblastoma. RECENT FINDINGS: Multimodality treatment is usually recommended for the majority of ONB cases. Recent advances in surgical approaches include the evolving role of endonasal endoscopic surgical resection and reconstruction. The introduction of new conformal radiation techniques has improved the outcomes and reduced treatment-related toxicity to important structures such as the eye and the brain...
February 7, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29411123/is-there-an-age-threshold-for-holding-off-on-testing-novel-therapies
#4
REVIEW
Olivia Le Saux, Claire Falandry
PURPOSE OF REVIEW: We will review the reasons that explain the poor accrual of elderly patients to clinical trials, then we will discuss the relevance of an age threshold for holding off on testing novel therapies. RECENT FINDINGS: Little progress has been made in enrolling elderly patients in clinical trials. Reasons to hold off on testing novel therapies in elderly patients are mainly explained by exclusion criteria and industrials' reluctance to include elderly patients for fear of negative results...
February 7, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29388071/yoga-for-the-management-of-cancer-treatment-related-toxicities
#5
REVIEW
Po-Ju Lin, Luke J Peppone, Michelle C Janelsins, Supriya G Mohile, Charles S Kamen, Ian R Kleckner, Chunkit Fung, Matthew Asare, Calvin L Cole, Eva Culakova, Karen M Mustian
PURPOSE OF REVIEW: To (1) explain what yoga is, (2) summarize published literature on the efficacy of yoga for managing cancer treatment-related toxicities, (3) provide clinical recommendations on the use of yoga for oncology professionals, and (4) suggest promising areas for future research. RECENT FINDINGS: Based on a total of 24 phase II and one phase III clinical trials, low-intensity forms of yoga, specifically gentle hatha and restorative, are feasible, safe, and effective for treating sleep disruption, cancer-related fatigue, cognitive impairment, psychosocial distress, and musculoskeletal symptoms in cancer patients receiving chemotherapy and radiation and cancer survivors...
February 1, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29383451/chronic-myeloid-leukemia-what-is-the-best-strategy-to-start-and-monitor-treatment-outside-academic-centers
#6
REVIEW
Carolina Pavlovsky, Maria Jose Mela Osorio
The introduction of tyrosine kinase inhibitors (TKI) has dramatically changed the outcome of chronic myeloid leukemia (CML). Over the last decade, imatinib positioned itself as the gold standard of care, until second-generation TKIs were introduced as first-line treatment. Multiple therapeutic options available today in CML make the decision of the first-line therapy a difficult choice. However, a gap still exists, in the management of CML outside academic centers. Important advances in molecular monitoring have been developed worldwide; nevertheless, monitoring in the "real world" continues to be a challenge in part because international scale (IS) standardized laboratories are not available worldwide, and also because physicians still have some resource barriers and lack of familiarity restricting guideline adoption and consider optimal molecular monitoring a challenge...
January 30, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29362905/role-of-chemotherapy-in-the-neoadjuvant-adjuvant-setting-for-patients-with-rectal-adenocarcinoma-undergoing-chemoradiotherapy-and-surgery-or-radiotherapy-and-surgery
#7
REVIEW
Shahab Ahmed, Cathy Eng
Rectal cancer has been successfully managed in the last couple of decades. In the USA, as the initial approach, neoadjuvant concurrent chemoradiation has been associated not only with decrease in tumor size and recurrence but also with higher resection rate with minimal side effects. Data support that addition of chemotherapy to radiotherapy is superior to radiotherapy alone in the neoadjuvant setting. Recent debates have addressed the question of administration of adjuvant chemotherapy following surgery. In this article, we discuss the role of chemotherapy in both the neoadjuvant and the adjuvant settings for locally advanced rectal cancer...
January 23, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29349566/performance-improvement-in-head-and-neck-cancer
#8
REVIEW
Carol M Lewis, Randal S Weber
Performance improvement requires establishing a platform to set benchmarks and monitor the quality of care provided through quality indicators and metrics. This has long been recognized as critical to overall quality improvement and more recently, has become federally mandated. Here, we review recent studies evaluating performance in head and neck cancer care, from those spanning all phases of head and neck cancer care to others focused on head and neck surgical performance, including both national and departmental/institutional efforts...
January 19, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29349518/checkpoint-inhibitors-palliative-care-or-hospice
#9
REVIEW
Mellar P Davis, Rajiv Panikkar
PURPOSE: Checkpoint (CTLA-4, PD-1, and PD-L1) inhibitors have changed the face of oncology. A subset of patients enjoys long, gratifying treatment responses. Unfortunately, most patients do not respond even when expressing favorably markers such as PD-L1. Checkpoint inhibitors are largely palliative (though a subset have long-term cancer responses) and as such patient-related outcome measures should be included when evaluating benefits. The purpose of this review is to place checkpoint inhibitor trials within a palliation context...
January 19, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29105030/what-s-new-in-imaging-for-gynecologic-cancer
#10
REVIEW
Sairah R Khan, Mubarik Arshad, Kathryn Wallitt, Victoria Stewart, Nishat Bharwani, Tara D Barwick
Magnetic resonance imaging (MRI) is the optimal modality for local staging of gynecological tumors. Advances in functional MRI with diffusion-weighted and dynamic contrast-enhanced sequences provide more detailed information regarding tumor cellularity, vascularity, and viability. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) now has an established role in imaging for gynecological cancers, particularly staging of locally advanced cervical cancers and pre-salvage exenterative therapy in relapsed gynecologic tumors...
November 6, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/29098465/a-metabolic-therapy-for-malignant-glioma-requires-a-clinical-measure
#11
REVIEW
Zachary Corbin, Daniel Spielman, Lawrence Recht
Cancers are "reprogrammed" to use a much higher rate of glycolysis (GLY) relative to oxidative phosphorylation (OXPHOS), even in the presence of adequate amounts of oxygenation. Originally identified by Nobel Laureate Otto Warburg, this hallmark of cancer has recently been termed metabolic reprogramming and represents a way for the cancer tissue to divert carbon skeletons to produce biomass. Understanding the mechanisms that underlie this metabolic shift should lead to better strategies for cancer treatments...
November 2, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/29081018/treatment-for-malignant-pheochromocytomas-and-paragangliomas-5%C3%A2-years-of-progress
#12
REVIEW
Paola Jimenez, Claudio Tatsui, Aaron Jessop, Sonali Thosani, Camilo Jimenez
PURPOSE OF REVIEW: The purpose of this manuscript is to review the progress in the field of therapeutics for malignant pheochromocytomas and sympathetic paraganglioma (MPPG) over the past 5 years. RECENT FINDINGS: The manuscript will describe the clinical predictors of survivorship and their influence on the first TNM staging classification for pheochromocytomas and sympathetic paragangliomas, the treatment of hormonal complications, and the rationale that supports the resection of the primary tumor and metastases in patients with otherwise incurable disease...
October 28, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/29080990/reirradiation-of-skull-base-tumors-with-advanced-highly-conformal-techniques
#13
REVIEW
Jennifer C Ho, Jack Phan
PURPOSE OF REVIEW: Skull base reirradiation is challenging due to complex anatomy, enrichment of treatment-resistant clonogens, and increased risk of severe treatment complications. Without local therapy, early mortality is certain and tumor progression can result in debilitating symptoms. Modern radiotherapy advancements, such as image-guided radiation therapy (IGRT), intensity-modulated radiation therapy (IMRT), particle therapy, and stereotactic radiation therapy (SRT), are attractive for skull base reirradiation...
October 28, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/29075865/treatment-of-glioblastoma-in-older-adults
#14
REVIEW
Kelly Braun, Manmeet S Ahluwalia
Glioblastoma is the most common primary malignant brain tumor diagnosed in the USA and is associated with a poor prognosis. The outcomes in elderly patients (more than 65 years of age) are worse when compared to those younger than age 65 at the time of diagnosis. Older patients are not always offered treatments that would otherwise be considered standard of care due to comorbidities and concerns about toxicity and tolerability. The initial European Organization for Research and Treatment of Cancer study that led to approval of temozolomide in glioblastoma excluded patients more than 70 years of age...
October 26, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/29043531/desmoplastic-small-round-cell-tumor-presenting-as-an-ocular-mass-unusual-localization-and-remarkable-surgical-approach
#15
REVIEW
H Bengu Cobanoglu, Ehab Y Hanna, Diana Bell, Bita Esmaeli
Desmoplastic small round cell tumor (DSRCT) is a rare tumor that was first described by Gerald and Rosai in 1989 as a mesenchymal entity. This tumor has a unique translocation t (11:22) (p:13, q:12) resulting in EWS/WT1 gene fusion that is diagnostic for DSCRT. The overall prognosis for desmoplastic small round cell tumor remains extremely poor, with reported rates of death as high as 90%. Although the majority of patients undergo chemotherapy following surgery, the prognosis has been shown to be independent of whether the surgical process preceded or followed chemotherapy...
October 18, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/29032389/complementary-and-integrative-medicine-in-hematologic-malignancies-questions-and-challenges
#16
REVIEW
Moshe Frenkel, Kenneth Sapire
Hematologic malignancies represent 9.7% of all cancers, making them the fourth most common type of cancer in the United States. The aggressive and complex treatments administered in hematologic malignancies result in a high burden of psychological needs. Complementary and integrative medicine (CIM) is becoming one of the options that patients use to address their distress during and after cancer treatments. It is not clear whether appropriate CIM can relieve distress in patients affected by these malignancies...
October 14, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/29030741/the-role-of-next-generation-sequencing-in-sarcomas-evolution-from-light-microscope-to-molecular-microscope
#17
REVIEW
Roman Groisberg, Jason Roszik, Anthony Conley, Shreyaskumar R Patel, Vivek Subbiah
PURPOSE OF REVIEW: Sarcomas are rare, heterogeneous group of soft tissue and bone tumors. Precise diagnosis of specific subtypes is challenging using conventional methods. Herein, we review the role of next-generation sequencing (NGS) technology that is used for rapid sequencing of DNA and RNA. RECENT FINDINGS: Recent sarcoma specific studies recommend that molecular genetic testing should be added at diagnosis for appropriate clinical management in addition to diagnosis by expert pathologists...
October 13, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28988389/treatment-free-remission-a-new-therapeutic-goal-in-chronic-myelogenous-leukemia
#18
REVIEW
Ahmed Gamal Elsayed, Roma Srivastava, Muhammad Omer Jamil
PURPOSE OF REVIEW: Chronic myelogenous leukemia (CML) is a chronic myeloproliferative neoplasm characterized by the presence of Philadelphia chromosome [t(9:22)] leading to the presence of pathognomonic fusion gene product, BCR-ABL1. This leads to constitutive activation of ABL1 kinase. CML was a difficult-to-treat illness until the advent of small molecule tyrosine kinase inhibitor (TKI), imatinib which revolutionized therapy of CML. Since then, multiple second- and third-generation TKIs have been formulated which have proven effective and has led to marked improvement in survival...
October 7, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28983799/b-vitamin-complex-and-chemotherapy-induced-peripheral-neuropathy
#19
REVIEW
Janet Schloss, Maree Colosimo
PURPOSE OF REVIEW: The purpose of this mini review is to evaluate the literature on B vitamins and chemotherapy-induced peripheral neuropathy. RECENT FINDINGS: One hundred and five journal articles were evaluated and nine manuscripts were included. There was one in vitro, one was an animal and seven were human studies. The in vitro study was a safety study on vitamin B6 and oxaliplatin which was not directly related to CIPN. The animal study evaluated vitamin B3 on paclitaxel administration with positive results...
October 5, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28971292/using-geriatric-assessment-strategies-to-lead-end-of-life-care-discussions
#20
REVIEW
Ashley Baronner, Amy MacKenzie
End-of-life discussions with geriatric oncology patients are a vital part of the comprehensive care of the senior adult patient. Developing a roadmap for these conversations can be challenging. Patients and caregivers may have expectations that are not concordant with what is reasonably achievable if the patient is frail. Measuring baseline cognition, nutritional status, and physical function and discussing goals of care are all essential pieces of information that can be obtained through a comprehensive geriatric assessment (CGA)...
October 2, 2017: Current Oncology Reports
journal
journal
34702
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"